On October 4, 2024 Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), reported it will present comprehensive preclinical data demonstrating the selectivity and activity of CLSP-1025, a TCE targeting a common p53 mutation, at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), being held November 8 – 10, 2024 in Houston, Texas and virtually (Press release, Clasp Therapeutics, OCT 4, 2024, View Source [SID1234647046]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: CLSP-1025, a novel bispecific T cell engager targeting a p53 R175H mutant peptide presented by HLA-A*02:01
Presentation Type: Poster
Abstract Number: 1061
Date and Time: Friday, November 8, 2024, at 9 a.m. CT – 7 p.m. CT
Location: Exhibit Halls AB, George R. Brown Convention Center in Houston, TX
Presenters: Justina X Caushi, Alec R Andrews, James Bingham, Lenore Cullen, Anthony S Gizzi, Gillian A Kingsbury, Kaleigh Krapfl, Madison Curtis Siok, Catherine Souza, Kate Stokes and Michael F Maloney